Lakewood-Amedex Biotherapeutics

Lakewood-Amedex Biotherapeutics is a clinical-stage biotechnology company dedicated to developing a new class of fast-acting, broad-spectrum antimicrobial drugs — Bisphosphocin® — for the treatment of infectious diseases and to reduce the threat posed by drug-resistant strains (including MRSA and VRE). Antimicrobial resistance (AMR) has become an increasingly severe global health crisis, causing nearly 5 million deaths worldwide. The company's core product is Nu-3, a topically administered antimicrobial gel currently in Phase 2 clinical trials for the treatment of mild infected diabetic foot ulcers (iDFU).